^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | epirubicin (Topoisomerase II inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Single Arm, Single Center Clinical Trial: Detecting Circulating Tumor DNA to Predict the Effect of Anthracycline-based Neoadjuvant Chemotherapy For HER-2-negative Middle or High Risk Breast Cancer
Excerpt:
...by needle or hollow needle aspiration biopsy pathology confirmed to stage II-III Luminal B type (except Her-2 positive) and triple-negative primary breast cancer patients. ...
Trial ID:
Source:
Title:
The efficacy and saftety of high-dose epirubicin as neoadjuvant chemotherapy in breast cancer of Chinese population: a prospective multicenter clinical study
Excerpt:
...The proven pathological diagnosis of Luminal B (Her-2 positive type is excluded) and triple-negative breast cancer by fine-needle or core needle biopsy with measurable tumor lesions ( at least 10 mm by 5 mm thin-slice CT or MRI scanning; at least 20 mm of maximal diameter by CT scannning) or measurable skin lumps ect.The gross lesions with the maximal diameter of at least 10 mm are also included; 3. ...
Trial ID:
Less C2 evidence
Source:
Title:
Drug resistance gene expression and chemotherapy sensitivity detection in Chinese women with different molecular subtypes of breast cancer
Published date:
11/15/2020
Excerpt:
The basal-like and HER2+ breast cancer primary cells showed chemosensitivities to paclitaxel and epirubicin with significant differences compared with luminal breast cancer primary cells (P < 0.05).
DOI:
10.20892/j.issn.2095-3941.2020.0157
